617 related articles for article (PubMed ID: 28356247)
21. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
Langner-Lemercier S; Houillier C; Soussain C; Ghesquières H; Chinot O; Taillandier L; Soubeyran P; Lamy T; Morschhauser F; Benouaich-Amiel A; Ahle G; Moles-Moreau MP; Moluçon-Chabrot C; Bourquard P; Damaj G; Jardin F; Larrieu D; Gyan E; Gressin R; Jaccard A; Choquet S; Brion A; Casasnovas O; Colin P; Reman O; Tempescul A; Marolleau JP; Fabbro M; Naudet F; Hoang-Xuan K; Houot R
Neuro Oncol; 2016 Sep; 18(9):1297-303. PubMed ID: 26951382
[TBL] [Abstract][Full Text] [Related]
22. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
[TBL] [Abstract][Full Text] [Related]
23. [Checkpoint inhibitors in Hodgkin lymphoma].
Sasse S; Momotow J; Engert A
Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic correlates of
Sethi TK; Kovach AE; Grover NS; Huang LC; Lee LA; Rubinstein SM; Wang Y; Morgan DS; Greer JP; Park SI; Ann Thompson-Arildsen M; Yenamandra A; Vnencak-Jones CL; Reddy NM
Leuk Lymphoma; 2019 Dec; 60(12):2880-2889. PubMed ID: 31184237
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab in the Treatment of Hodgkin Lymphoma.
Ansell SM
Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
[TBL] [Abstract][Full Text] [Related]
26. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma.
Melani C; Major A; Schowinsky J; Roschewski M; Pittaluga S; Jaffe ES; Pack SD; Abdullaev Z; Ahlman MA; Kwak JJ; Morgan R; Rabinovitch R; Pan Z; Haverkos BM; Gutman JA; Pollyea DA; Smith CA; Wilson WH; Kamdar M
N Engl J Med; 2017 Jul; 377(1):89-91. PubMed ID: 28679093
[No Abstract] [Full Text] [Related]
27. Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report.
Furuse M; Nonoguchi N; Omura N; Shirahata M; Iwasaki K; Inui T; Kuroiwa T; Kuwabara H; Miyatake SI
Neurol Med Chir (Tokyo); 2017 Apr; 57(4):191-197. PubMed ID: 28331101
[TBL] [Abstract][Full Text] [Related]
28. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
29. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
[TBL] [Abstract][Full Text] [Related]
30. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.
Qin Q; Nan X; Miller T; Fisher R; Teh B; Pandita S; Farach AM; Pingali SR; Pandita RK; Butler EB; Pandita TK; Iyer SP
Radiat Res; 2018 Sep; 190(3):322-329. PubMed ID: 29949442
[TBL] [Abstract][Full Text] [Related]
31. [PD-1 blockade therapy in lymphoid malignancies].
Nishikori M; Takaori-Kondo A
Rinsho Ketsueki; 2017; 58(10):2043-2049. PubMed ID: 28978847
[TBL] [Abstract][Full Text] [Related]
32. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model.
Qiu Y; Li Z; Pouzoulet F; Vishnu P; Copland JA; Knutson KL; Soussain C; Tun HW
Br J Haematol; 2018 Nov; 183(4):674-678. PubMed ID: 29076134
[No Abstract] [Full Text] [Related]
34. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.
Tanvetyanon T; Creelan BC; Antonia SJ
Expert Rev Anticancer Ther; 2016 Sep; 16(9):903-10. PubMed ID: 27488231
[TBL] [Abstract][Full Text] [Related]
35. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
[TBL] [Abstract][Full Text] [Related]
36. PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety.
Chan TSY; Li J; Loong F; Khong PL; Tse E; Kwong YL
Ann Hematol; 2018 Jan; 97(1):193-196. PubMed ID: 28879531
[No Abstract] [Full Text] [Related]
37. Complete response to anti-PD-1 nivolumab in massive skin metastasis from melanoma: efficacy and tolerability in an elderly patient.
Sponghini A; Patrucco F; Giorgione R; Farinelli P; Zottarelli F; Rondonotti D; Savoia P
Anticancer Drugs; 2017 Aug; 28(7):808-810. PubMed ID: 28489616
[TBL] [Abstract][Full Text] [Related]
38. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
[TBL] [Abstract][Full Text] [Related]
39. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
[TBL] [Abstract][Full Text] [Related]
40. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]